**Supplementary Table 1: Chemotherapeutic response according to clinicopathological parameters.**

| | | Response after neoadjuvant chemotheraoy | | Test value | Pvalue | Sig. |
|---|---|---|---|---|---|---|
| | | No (SD+PD) | Yes (CR+PR) | | | |
| | | No. = 12 | No. = 30 | | | |
| Age | Mean ± SD | 49 ± 7 | 48 ± 10 | **0.336•** | 0.738 | NS |
| | Range | 37 – 60 | 31 – 70 | | | |
| | < 50 yrs | 7 (58.3%) | 17 (56.7%) | **0.010*** | 0.921 | NS |
| | >=50 yrs | 5 (41.7%) | 13 (43.3%) | | | |
| Initial Size (cm) | Mean ± SD | 6.12 ± 1.55 | 5.59 ± 1.48 | **1.046•** | 0.302 | NS |
| | Range | 3.4 – 9 | 2 – 8.5 | | | |
| FIGO2018 staging | Stage 2A | 0 (0.0%) | 2 (6.7%) | **5.778*** | 0.328 | NS |
| | Stage 3A | 1 (8.3%) | 0 (0.0%) | | | |
| | Stage 4A | 1 (8.3%) | 2 (6.7%) | | | |
| | **Stage 2b** | **4 (33.3%)** | **12 (40.0%)** | | | |
| | Stage 3b | 2 (16.7%) | 1 (3.3%) | | | |
| | **Stage 3c** | **4 (33.3%)** | **13 (43.3%)** | | | |
| Grade | Grade 1 | 0 (0.0%) | 2 (6.7%) | **2.494*** | 0.287 | NS |
| | Grade 2 | 9 (75.0%) | 15 (50.0%) | | | |
| | Grade 3 | 3 (25.0%) | 13 (43.3%) | | | |
| Type of pathology | Sq.C.C G | 11 (91.7%) | 27 (90.0%) | **3.703*** | 0.295 | NS |
| | Undifferentiated carcinoma | 0 (0.0%) | 2 (6.7%) | | | |
| | Adenocarcinoma | 0 (0.0%) | 1 (3.3%) | | | |
| | Adeno.with seq.diff. | 1 (8.3%) | 0 (0.0%) | | | |
| Chemotherapy regularity | Not compliant | 2 (16.7%) | 1 (3.3%) | **2.297*** | 0.130 | NS |
| | Compliant | 10 (83.3%) | 29 (96.7%) | | | |
| Duration of follow up (months) | Mean ± SD | 13.58 ± 4.83 | 13.67 ± 4.89 | **-0.050•** | 0.960 | NS |
| | Range | 7 – 22 | 5 – 24 | | | |

P-value > 0.05: not significant; P-value < 0.05: significant; P value < 0.01: highly significant.

*: Chi-square test; •: Independent t- test

**Supplementary Table 2 : OS analysis for the study group.**

| Total N | N of Events | OS (months) | | 95% CI | | Survival at | | |
|---|---|---|---|---|---|---|---|---|
| | | Mean | S.E | Lower | Upper | 9 months | 12 months | 15 months |
| 38 | 6 | 21.341 | 0.983 | 19.415 | 23.267 | 94.4% | 84.4% | 79.1% |

**Supplementary Table 3: Relationships of stage, response and treatment per protocol with overall survival of the studied patients according to Kaplan–Meier analysis**

| | | Total N | N of deaths | OS (months) | | 95% CI | | Survival at (%) | | | Log Rank Test | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Mean | SE | Lower | Upper | 6 months | 9 months | 12 months | X2 | Pvalue | Sig. |
| Stage | Stage 2B | 16 | 1 | 22.867 | 1.095 | 20.721 | 25.013 | 100.0% | 93.3% | 93.3% | 0.738 | 0.390 | NS |
| | Stage 3C | 15 | 3 | 20.500 | 1.269 | 18.013 | 22.987 | 100.0% | 100.0% | 85.7% | | | |
| Response | Non responder | 10 | 3 | 22.867 | 1.095 | 20.721 | 25.013 | 100.0% | 80.0% | 70.0% | 1.314 | 0.252 | NS |
| | Responder | 28 | 3 | 20.500 | 1.269 | 18.013 | 22.987 | 100.0% | 100.0% | 95.7% | | | |
| Treatment per protocol | Not treated per protocol | 7 | 4 | 13.571 | 1.915 | 9.818 | 17.325 | 100.0% | 71.4% | 42.9% | 9.303 | 0.002 | HS |
| | Treated per protocol | 31 | 2 | 22.834 | .790 | 21.285 | 24.383 | 100.0% | 96.2% | 96.2% | | | |

**Supplementary Table 4: Progression -free survival analysis for the study group.**

| Total N | N of Events | PFS (months) | | 95% CI | | PFS at | | |
|---|---|---|---|---|---|---|---|---|
| | | Mean | S.E | Lower | Upper | 6 months | 9 months | 12 months |
| 38 | 10 | 18.65 | 1.173 | 16.349 | 20.949 | 94.7% | 80.8% | 70.4% |

**Supplementary Table 5: Relationships of stage, response and receiving standard treatment with progression-free survival in the studied patients according to Kaplan–Meier analysis**

| | | Total N | N of deaths | PFS (months) | | 95% CI | | Survival at (%) | | | Log Rank Test | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | Mean | SE | Lower | Upper | 6 months | 9 months | 12 months | X2 | Pvalue | Sig. |
| Stage | Stage 2B | 16 | 1 | 22.923 | 1.035 | 20.895 | 24.951 | 100.0% | 100.0% | 92.3% | 2.369 | 0.124 | NS |
| | Stage 3C | 16 | 5 | 18.326 | 1.756 | 14.885 | 21.767 | 93.8% | 80.4% | 67.0% | | | |
| Response | Non responder | 11 | 4 | 16.341 | 2.255 | 11.922 | 20.760 | 90.9% | 71.6% | 61.4% | 1.644 | 0.200 | NS |
| | Responder | 29 | 5 | 20.861 | 1.260 | 18.391 | 23.331 | 96.6% | 89.1% | 78.6% | | | |
| Treatment per protocol | Not treated per protocol | 8 | 3 | 13.975 | 2.289 | 9.488 | 18.462 | 87.5% | 60.0% | 60.0% | 1.660 | 0.198 | NS |
| | Treated per protocol | 32 | 6 | 20.705 | 1.199 | 18.355 | 23.055 | 96.9% | 90.2% | 77.5% | | | |

**Supplementary Table 6. Adverse events during NACT (a) and CCRT (b) assessment according to CTCAEv.5.0 [16].**

| (a) Toxicities | NACT (42 patients) |
|---|---|
| Neutropenia<br>G1/G2/G≥3 | 3 (7.14%)/8 (19%)/5 (11.9%) |
| Anemia<br>G1/G2/G≥3 | 9 (21.4%)/15 (35.7%)/4 (9.5%) |
| Thrombocytopenia<br>G1/G2/G≥3 | 2 (4.8%)/1 (2.4%)/---- |
| Neurotoxicity<br>G1/G2/G≥3 | 3 (7.1%)/3 (7.1%)/----- |
| Vomiting<br>G1/G2/G≥3 | 2 (4.8%)/-----/----- |
| Diarrhea<br>G1/G2/G≥3 | 4 (9.5%)/-----/----- |
| Alopecia<br>G1/G2/G≥3 | ----/32 (76.19%)/----- |
| Hepatotoxicity<br>G1/G2/G≥3 | 1 (2.4%)/----/---- |
| Renal impairement<br>G1/G2/G≥3 | 1 (2.4%)/-----/----- |
| Oral mucositis<br>G1/G2/G≥3 | 2 (4.8%)/-----/----- |
| Hypersensitivity<br>G1/G2/G≥3 | ----/4 (9.5%)/---- |

*No toxicity = 8 patients; 34 patients developed toxicity

| (b) Toxicities | CCRT/RT (41 patients *) |
|---|---|
| Neutropenia<br>G1/G2/G≥3 | 6 (14.6%)/2 (4.9%)/3 (7.3%) |
| Anemia<br>G1/G2/G≥3 | 5 (12.2%)/8 (19.5%)/4 (9.8%) |
| Thrombocytopenia<br>G1/G2/G≥3 | 5 (12.2%)/1 (2.4%)/1 (2.4%) |
| Neurotoxicity<br>G1/G2/G≥3 | 1 (2.4%)/2 (4.9%)/1 (2.4%) |
| Vomiting<br>G1/G2/G≥3 | ----/1(2.4%)/---- |
| Diarrhea<br>G1/G2/G≥3 | 2 (4.9%)/1(2.4%)/1 (2.4%) |
| Dermatitis<br>G1/G2/G≥3 | 2 (4.9%)/----/---- |
| Renal impairement<br>G1/G2/G≥3 | ----/6 (14.6%)/3 (7.3%) |

*No toxicity =11 patients; 30 patients developed toxicity.